Hematologists near Paramus, NJ

Biography: Dr. Lentzsch is a Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She is at New York Presbyterian Hospital/ Columbia University Medical Center. After receiving her degrees from the Humboldt University/ Charit Berlin, Germany, she completed her residency and fellowship at Humboldt University. She did a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, MA, USA. Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, Multiple Myeloma, Amyloidosis, POEMS and Waldenstrom's Macroglobulinemia. Dr. Lentzsch is an internationally recognized expert in the field of Multiple Myeloma and Amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of Secondary Primary Malignancies associated with IMiDs.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Care Philosophy: The ability to work closely with patients and with specialists in a variety of fields to solve complex clinical questions draws me to the field of non-malignant hematology. I am lucky to have had the opportunity to train under brilliant thinkers and exceptional role models from whom I have learned the importance of ensuring that each patient truly understands his or her diagnosis and the rationale behind treatment. I am excited to be joining the Department of Hematology at Weill Cornell and look forward to continuing in clinical investigations in hopes of improving diagnosis and treatment in the fields of thrombosis and immune thrombocytopenia. We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Pawel Muranski, MD, trained as a Hematologist and Oncologist at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH) in Bethesda, Maryland where he subsequently worked as a faculty in the Stem Cell Allogeneic Transplantation Section. He joined Columbia University in 2017 as the Director of Cellular Immunotherapy. Dr. Muranski specializes in bone marrow transplant (BMT).

Biography: Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow. Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Biography: Rajshekhar Chakraborty, MD is an assistant professor of medicine at Columbia University Irving Medical Center in the division of hematology/oncology. After receiving his medical degree from University of Delhi, India, he completed his residency in internal medicine at Icahn School of Medicine at Mount Sinai-Queens Hospital Center. Subsequently, he spent three years as a clinical researcher in plasma cell disorders at the Mayo Clinic, Rochester, followed by fellowship in hematology/oncology at the Cleveland Clinic. During fellowship, he conducted outcomes research with a focus on quality of life and treatment-related toxicities in plasma cell disorders. After fellowship, he started his job as Assistant Professor of Medicine at the Multiple Myeloma and Amyloidosis Program at Columbia University Irving Medical Center. Dr. Chakraborty cares primarily for patients with plasma cells disorders, including multiple myeloma, amyloidosis, MGUS, POEMS syndrome, and Waldenstrom's macroglobulinemia. His research interests include clinical trials and outcomes research in plasma cell disorders.

Biography: My expertise is in pediatric hematology and oncology, with a particular focus on leukemias and lymphomas, or cancers of the blood, bone marrow, or lymph nodes. I am especially interested in chronic myeloid leukemia (CML). Because children are growing and developing, CML treatment and management present unique challengesthe same treatment options that work best for grown-ups may not be the right strategies for kids. I treat children, adolescents, and young adults. I love working with this population and developing long-lasting relationships with my young patients. I am especially passionate about delivering personalized care to each of thembecause no two kids are the same. Diseases like leukemia and lymphoma are challenging for anyone, but they can be especially hard on children. Symptoms like fatigue and joint pain can make it hard to move, play, and act like a kid, and some treatments can have severe side effects. I work to manage children's symptoms and choose the right treatments for their disease, based on their individual needs. Helping these children is the most satisfying goal I can imagine. My research revolves around the treatment of pediatric leukemias and lymphomas. I continue to explore the impact of current treatments, and I collaborate with basic science researchers to translate their breakthroughs into new drug development. I have also been involved in cancer survivorship research. As a professor and the section head of pediatric oncology, I am deeply committed to educating and mentoring medical students, residents, and fellows and helping to prepare the next generation of leaders in pediatric hematology/oncology.

Biography: Margaret T Lee, MD cares for children with blood disorders, such as anemias (sickle cell anemia, thalassemia, and iron deficiency), bleeding (including idiopathic thrombocytopenic purpura [ITP], hemophilia, and von Willebrand disease), and clotting disorders (such as deep vein thrombosis). Dr. Lee's area of interest is a rare group of diseases called vascular anomalies. There is relatively little known about these disorders, and the care of patients with vascular anomalies requires a multidisciplinary group of physicians from several specialties (dermatology, surgery, cardiology, neurology, and hematology/oncology)-all of whom are available at NewYork-Presbyterian/Morgan Stanley Children's Hospital. Hematologists play a role in the medical treatment of vascular tumors and the supportive care of clotting and bleeding complications that are associated with some types of vascular malformations. Dr. Lee is an active participant in the Vascular Anomalies Group at NYP/Morgan Stanley Children's Hospital, as well as the Vascular Anomalies Special Interest Group of the American Society of Pediatric Hematology/Oncology, which is looking at novel therapies for vascular anomalies and their complications.

Biography: Diane George, MD cares for children and adolescents undergoing stem cell transplantation as a treatment for cancer (particularly leukemia and lymphoma), noncancerous blood disorders (like sickle cell anemia), and immunodeficiencies. She specializes in transplantation for patients who don't have a related bone marrow donor, and also takes care of patients undergoing autologous stem cell transplantation for solid tumors. Dr. George was originally attracted to the field of pediatric oncology because she wanted to take on the challenge of fighting pediatric cancer, and stem cell transplantation offers the ultimate cure in select patients. It is a complex medical field, and Dr. George enjoys being able to take care of children with complex medical conditions. Dr. George also conducts clinical research. She is currently evaluating a procedure called "CD34-selected stem cell transplantation" to remove T-cells from donor bone marrow. This approach reduces the risk of graft-versus-host disease (GVHD) - a potential complication of bone marrow transplantation in which T-cells from the donor attack the tissue of the recipient. This approach benefits patients who do not have a well-matched family donor, and it could potentially make bone marrow transplantation an option for more patients. Dr. George is also interested in studying how a patient's immune system rebuilds itself after CD34-selected stem cell transplantation. At NewYork-Presbyterian/Morgan Stanley Children's Hospital, every member of a child's healthcare team shares the same compassion and dedication to helping them get well. Dr. George looks forward each day to the camaraderie, intellectual stimulation, and problem-solving she shares with fellow team members. After being in the field for more than 20 years, Dr. George uses the knowledge and experience she has gained to benefit patients and their families.

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience We are devoted to providing services that are patient centered and compassionate and care for you as a person nbsp;

Biography: Dr. Reshef trained in Hematology, Oncology and Bone Marrow Transplantation and received a Master of Science degree in Translational Research from the University of Pennsylvania. He joined Columbia University in 2015 as Director of Translational Research for the Blood and Marrow Transplantation program. He is the Clinical Lead for the CAR-T Cell Program at Columbia, a principal investigator at the Columbia Center for Translational Immunology and a member of the Herbert Irving Comprehensive Cancer Center.

Biography: Prakash Satwani, MD specializes in the use of bone marrow transplantation to treat children and adolescents with leukemia, lymphoma, or hemophagocytic lymphohistiocytosis. Bone marrow transplantation is a dynamic, intriguing field with multiple complex issues. Dr. Satwani has always enjoyed solving puzzles and is attracted to the intellectual challenge of caring for patients whose lives may be saved or extended with bone marrow transplantation. Dr. Satwani is also inspired and motivated by the long-lasting and rich relationships formed with patients and their families, and often keeps in touch with families long after their child's treatment has been completed. Dr. Satwani teaches medical students, residents, fellows, nurses, and nurse practitioners about bone marrow transplantation. It's important to educate people so they can learn the latest advances and provide the best care possible for patients. To continue to achieve those advances, Dr. Satwani conducts clinical research in reducing the life-threatening complications related to transplantation, such as infections and graft-versus-host disease. Dr. Satwani and colleagues also evaluate reduced-intensity bone marrow transplantation preparative regimens, which use lower doses of chemotherapy with the hope of decreasing short-term and long-term complications without compromising the effectiveness of treatment.